[go: up one dir, main page]

HN2010000081A - Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva - Google Patents

Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva

Info

Publication number
HN2010000081A
HN2010000081A HN2010000081A HN2010000081A HN2010000081A HN 2010000081 A HN2010000081 A HN 2010000081A HN 2010000081 A HN2010000081 A HN 2010000081A HN 2010000081 A HN2010000081 A HN 2010000081A HN 2010000081 A HN2010000081 A HN 2010000081A
Authority
HN
Honduras
Prior art keywords
stratriens
strogens
beta
substituted
preparations
Prior art date
Application number
HN2010000081A
Other languages
English (en)
Inventor
Peters Olaf
Braeuer Nico
Thieme Ina
Prelle Katja
Peter Muhn Hans
Fritzemeier Karl-Heinrich
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HN2010000081A publication Critical patent/HN2010000081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE A DERIVADOS DE ESTRA -1, 3,5 (10)-TRIENO 8 SUSTITUIDOS DE FORMULA GENERAL I SU USO COMO INGREDIENTES FARMACEUTICOS ACTIVOS QUE TIENEN UNA MAYOR AFINIDAD IN VITRO POR PREPARACIONES DE RECEPTORES DE ESTROGENO DE PROSTATA DE RATA QUE POR PREPARACIONES DE RECEPTORES DE ESTROGENO DE UTERO DE RATA Y QUE PRESENTA UNA ACCION PREFERENCIAL IN VIVO EN EL OVARIO EN COMPARACION CON EL UTERO, CON SU PRODUCCION SU USO TERAPEUTICO, Y CON FORMAS DE ADMINISTRACION QUE CONTIENEN LOS NUEVOS COMPUESTOS.
HN2010000081A 2007-07-12 2010-01-12 Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva HN2010000081A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07075600A EP2014672A1 (en) 2007-07-12 2007-07-12 8-beta-substituted estratrienes as selectively active estrogens

Publications (1)

Publication Number Publication Date
HN2010000081A true HN2010000081A (es) 2013-07-01

Family

ID=38657613

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010000081A HN2010000081A (es) 2007-07-12 2010-01-12 Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva

Country Status (34)

Country Link
US (1) US20090029957A1 (es)
EP (2) EP2014672A1 (es)
JP (1) JP2010533152A (es)
KR (1) KR20100037593A (es)
CN (1) CN101687902B (es)
AR (1) AR067507A1 (es)
AU (1) AU2008274198A1 (es)
BR (1) BRPI0814207A2 (es)
CA (1) CA2692727A1 (es)
CL (1) CL2008002027A1 (es)
CO (1) CO6270230A2 (es)
CR (1) CR11211A (es)
CU (1) CU23885B1 (es)
CY (1) CY1113351T1 (es)
DK (1) DK2176282T3 (es)
DO (1) DOP2010000017A (es)
EA (1) EA017124B1 (es)
EC (1) ECSP109872A (es)
ES (1) ES2393942T3 (es)
HN (1) HN2010000081A (es)
HR (1) HRP20120952T1 (es)
MA (1) MA31565B1 (es)
NZ (1) NZ582490A (es)
PA (1) PA8789401A1 (es)
PE (1) PE20090825A1 (es)
PL (1) PL2176282T3 (es)
PT (1) PT2176282E (es)
RS (1) RS52541B (es)
SI (1) SI2176282T1 (es)
TN (1) TN2010000007A1 (es)
TW (1) TW200911824A (es)
UA (1) UA99918C2 (es)
UY (1) UY31220A1 (es)
WO (1) WO2009007454A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508784A (ja) * 2011-03-25 2014-04-10 ユニヴェルシテ ラヴァル １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤
CN110177610A (zh) * 2016-06-24 2019-08-27 K&N工程公司 复合式空气过滤器及其方法
USD905747S1 (en) 2018-04-09 2020-12-22 Mitsubishi Electric Corporation Display screen with animated graphical user interface

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1272505T3 (da) * 2000-04-12 2005-11-07 Schering Ag 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene

Also Published As

Publication number Publication date
DK2176282T3 (da) 2012-12-03
CA2692727A1 (en) 2009-01-15
AU2008274198A1 (en) 2009-01-15
PT2176282E (pt) 2012-11-30
PL2176282T3 (pl) 2013-06-28
RS52541B (sr) 2013-04-30
CN101687902B (zh) 2013-07-24
EP2176282B1 (en) 2012-08-22
CY1113351T1 (el) 2016-06-22
TW200911824A (en) 2009-03-16
CN101687902A (zh) 2010-03-31
CO6270230A2 (es) 2011-04-20
WO2009007454A2 (en) 2009-01-15
CR11211A (es) 2010-04-27
MA31565B1 (fr) 2010-08-02
UY31220A1 (es) 2009-03-02
NZ582490A (en) 2012-03-30
KR20100037593A (ko) 2010-04-09
TN2010000007A1 (en) 2011-09-26
AR067507A1 (es) 2009-10-14
ECSP109872A (es) 2010-02-26
JP2010533152A (ja) 2010-10-21
CU20100008A7 (es) 2011-05-27
PE20090825A1 (es) 2009-07-25
ES2393942T3 (es) 2013-01-02
EA017124B1 (ru) 2012-10-30
HRP20120952T1 (hr) 2012-12-31
CU23885B1 (es) 2013-04-19
EP2014672A1 (en) 2009-01-14
BRPI0814207A2 (pt) 2015-01-27
WO2009007454A3 (en) 2009-03-05
UA99918C2 (ru) 2012-10-25
US20090029957A1 (en) 2009-01-29
CL2008002027A1 (es) 2009-01-16
EA201000097A1 (ru) 2010-08-30
SI2176282T1 (sl) 2013-02-28
DOP2010000017A (es) 2010-01-31
EP2176282A2 (en) 2010-04-21
PA8789401A1 (es) 2009-04-23

Similar Documents

Publication Publication Date Title
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
ECSP088239A (es) Composición de liberación de fármaco sostenida
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CR8529A (es) Nueva forma cristalina v de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contiene
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
GT201100195A (es) Derivados de sulfonamida
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
BR112012010083B8 (pt) Composição farmacêutica tópica de liberação sustentada e uso relacionado
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
TN2012000261A1 (en) Aerosol formulation for copd
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.
HN2010000081A (es) Estratrienos 8-beta-sustituidos como estrogenos de accion selectiva
UY32005A (es) Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a
ECSP055530A (es) Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
UA108865C2 (uk) Парентеральна фармацевтична композиція у вигляді суспензії уповільненого вивільнення, у низькій та наднизькій дозованій формі, у гормональній терапії при клімактеричному синдромі